CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti
The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for...
Sanofi
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...
Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion
France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3...
Sanofi’s Hornstein Sees China’s Online Hospitals Boosting Digital Health Strategy
Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online...
Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development
Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical...
ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor
Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...
Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China
Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...